Matthew Luchini
Stock Analyst at BMO Capital
(1.10)
# 3,576
Out of 4,761 analysts
50
Total ratings
32.14%
Success rate
-8.73%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Luchini
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Outperform | $51 → $30 | $13.98 | +114.59% | 4 | Mar 18, 2022 | |
| JSPR Jasper Therapeutics | Initiates: Outperform | $190 | $5.96 | +3,087.92% | 1 | Oct 20, 2021 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $89 → $69 | $27.52 | +150.73% | 3 | Sep 10, 2021 | |
| KOD Kodiak Sciences | Maintains: Market Perform | $138 → $104 | $4.45 | +2,237.08% | 3 | May 11, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $55 | $3.01 | +1,727.24% | 1 | Mar 31, 2021 | |
| ARVN Arvinas | Initiates: Outperform | $101 | $17.77 | +468.37% | 2 | Mar 31, 2021 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Outperform | $630 | $700.33 | -10.04% | 13 | Jan 25, 2021 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Market Perform | $119 → $124 | $336.23 | -63.12% | 2 | Nov 6, 2020 | |
| BLUE bluebird bio | Downgrades: Market Perform | $1,120 | $4.08 | +27,350.98% | 11 | Nov 5, 2020 | |
| GILD Gilead Sciences | Maintains: Market Perform | $74 → $64 | $109.95 | -41.79% | 2 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $14 | $34.07 | -58.91% | 1 | Jun 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $47 → $60 | $1.96 | +2,961.22% | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $120 → $164 | $1.31 | +12,449.62% | 5 | Mar 8, 2018 |
Replimune Group
Mar 18, 2022
Maintains: Outperform
Price Target: $51 → $30
Current: $13.98
Upside: +114.59%
Jasper Therapeutics
Oct 20, 2021
Initiates: Outperform
Price Target: $190
Current: $5.96
Upside: +3,087.92%
Apellis Pharmaceuticals
Sep 10, 2021
Maintains: Outperform
Price Target: $89 → $69
Current: $27.52
Upside: +150.73%
Kodiak Sciences
May 11, 2021
Maintains: Market Perform
Price Target: $138 → $104
Current: $4.45
Upside: +2,237.08%
C4 Therapeutics
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $3.01
Upside: +1,727.24%
Arvinas
Mar 31, 2021
Initiates: Outperform
Price Target: $101
Current: $17.77
Upside: +468.37%
Regeneron Pharmaceuticals
Jan 25, 2021
Upgrades: Outperform
Price Target: $630
Current: $700.33
Upside: -10.04%
Madrigal Pharmaceuticals
Nov 6, 2020
Maintains: Market Perform
Price Target: $119 → $124
Current: $336.23
Upside: -63.12%
bluebird bio
Nov 5, 2020
Downgrades: Market Perform
Price Target: $1,120
Current: $4.08
Upside: +27,350.98%
Gilead Sciences
Oct 29, 2020
Maintains: Market Perform
Price Target: $74 → $64
Current: $109.95
Upside: -41.79%
Jun 5, 2020
Initiates: Outperform
Price Target: $14
Current: $34.07
Upside: -58.91%
Dec 3, 2019
Downgrades: Market Perform
Price Target: $47 → $60
Current: $1.96
Upside: +2,961.22%
Mar 8, 2018
Maintains: Market Perform
Price Target: $120 → $164
Current: $1.31
Upside: +12,449.62%